LO9A Stock Overview
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VBI Vaccines Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.56 |
| 52 Week High | US$2.91 |
| 52 Week Low | US$0.44 |
| Beta | 1.92 |
| 1 Month Change | -0.89% |
| 3 Month Change | n/a |
| 1 Year Change | -80.93% |
| 3 Year Change | -99.19% |
| 5 Year Change | -98.93% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| LO9A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -36.6% | -4.3% | -2.5% |
| 1Y | -80.9% | -19.4% | -0.4% |
Return vs Industry: LO9A underperformed the German Biotechs industry which returned -15.8% over the past year.
Return vs Market: LO9A underperformed the German Market which returned 1% over the past year.
Price Volatility
| LO9A volatility | |
|---|---|
| LO9A Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LO9A's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LO9A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 193 | Jeff Baxter | www.vbivaccines.com |
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
VBI Vaccines Inc. Fundamentals Summary
| LO9A fundamental statistics | |
|---|---|
| Market cap | €16.49m |
| Earnings (TTM) | -€87.25m |
| Revenue (TTM) | €8.16m |
2.0x
P/S Ratio-0.2x
P/E RatioIs LO9A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LO9A income statement (TTM) | |
|---|---|
| Revenue | US$8.68m |
| Cost of Revenue | US$12.51m |
| Gross Profit | -US$3.82m |
| Other Expenses | US$89.01m |
| Earnings | -US$92.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.28 |
| Gross Margin | -44.06% |
| Net Profit Margin | -1,069.29% |
| Debt/Equity Ratio | 674.5% |
How did LO9A perform over the long term?
See historical performance and comparison